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Effects on vital signs after twenty minutes of vaping compared 
to people exposed to second-hand vapor
Abstract
Introduction: Very little is known about the immediate physiological implications of vaping or inhaling second-hand vapor. This 
study used a quantitative approach to understand the short-term physiological implications of vape use and exposure to sec-
ond-hand vapor for people who do not vape. 
Material and methods: One hundred and forty-eight people participated in the study, 75 self-identified as non-vapers and 73 
self-identified as people who vape. All participants were over the age of 18. Participants used or were exposed to non-flavored 
e-juice without nicotine in Sorin® vape devices. Heart rate, blood pressure, respiratory rate, blood oxygenation, blood glucose 
and pulmonary function tests were assessed. Physiological parameters were assessed prior to vape use or exposure to vapor 
and again after 20 minutes of vaping. 
Results: Findings indicated there were no significant changes in most health parameters except blood pressure which was 
reduced in both groups. Heart rate was also significantly reduced for vaping participants. 
Conclusion: Vaping without flavorings or nicotine do not appear to have an immediate negative health impact on vital signs. 
The physiological effects of long-term exposure and/or vape use requires additional investigation. Information was established 
regarding the physiological effects of non-flavored, non-nicotine vaping so future studies can compare the effects of vaping with 
assorted flavors and nicotine concentrations to the effects of vaping only the base ingredients (vegetable glycerin and propylene 
glycol). New knowledge was gleaned relating to exposure to vapor, a phenomenon not previously examined but common espe-
cially among non-vaping people who attend social events where people are vaping.
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Introduction
The public health impact of vaping has be-
come a frequently discussed topic [1] but very 
little is currently known about the immediate 
physiological impact of vaping or second-hand 
exposure to vapor. The paucity of information 
related to the physiological effects of vaping is 
presenting problems for the medical community 
in knowing how to advise patients regarding 
vape use. This study was aimed at investigating 
the immediate physiological effects of vape use 
compared to second-hand exposure to vapor 
and to also better understand the demographics 
between the two groups.
Patented in 2003 but developed in 1963, vap-
ing was established as an alternative to cigarette 
smoking [2]. The incidence of vape use is on the 
rise [3, 4]. and has recently been subjected to 
regulations under the United States (US) Federal 
Food, Drug and Cosmetic Act [5]. The new reg-
ulations include restricting sales to minors and 
listing health warnings on labels. US Federal reg-
ulations were implemented because, despite not 
containing any tobacco, the US Center for Disease 
Control and the US Federal Drug Administration 
consider vapes to be tobacco products and poten-
tially harmful to health [3, 6, 7]. 
Since vaping is a fairly new phenomenon, 
there remains a lack of research regarding the 
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effects of its use and medical implications. Some 
reports suggest that vaping helps people quit 
smoking [9, 10]. Other reports suggest that vaping 
can actually improve some health conditions such 
as tonsilitis [11], that it can reverse symptoms of 
chronic idiopathic neutrophilia [12], and that it can 
improve and enhance a sense of well-being [13].
Vaping is typically regarded as a safer alter-
native to cigarette smoking under the assumption 
that vaping is less toxic than tobacco use [14–17]. 
Some researchers are suggesting that adult smok-
ers could vape as a means to reduce or quit smok-
ing tobacco cigarettes [18, 19]. 
But other studies indicate that vaping can 
actually lead to nicotine addiction and can have 
serious negative medical implications [20]. 
Emerging animal studies are suggesting that va-
ping may have negative health consequences. For 
example, an increased susceptibility to infections 
was found in mice when exposed to vapor [21]. 
Increased bacterial growth, formation of bio-
films, alterations in immunity, and disturbances 
in airway cytokines were other negative health 
effects found in animals exposed to vapor [22]. 
The high temperatures used to heat inhaled vape 
fluid are leading to the formation of toxins such 
as acrolein, acetaldehyde, and formaldehyde in 
the pulmonary system [23, 24]. Alterations in 
physiological hemostasis, hyperactive platelet 
activity, and an increased risk for thrombogenic 
events were also discovered [25]. 
Human vaping studies are suggesting con-
cerning health outcomes including lung diseases 
[26], cancer, cardiovascular disorders [27], head-
aches, bleeding from the nares, weight changes 
[28, 29], dizziness, nausea, and tremors [30]. 
Reports of heart attacks and seizures are also 
emerging as alarming health problems thought 
to be linked to vape use [31]. 
Additionally, the US FDA has deemed vaping 
to be potentially harmful to humans because of 
the nitrosamines, diethylene glycol, rimonabant, 
heavy metal, formaldehyde, acetaldehyde, and 
other contaminants found after using the devices 
[32]. As such, they have recently implemented 
new regulations and restrictions for sellers of 
vape products [5]. 
Health effects of base solvents in vape fluid
Most vape fluid contains vegetable glycer-
ine and propolyene glycol as the base ingredi-
dents. These FDA approved food ingredients may 
have concerning health effects when inhaled. Cer-
vellati et al15 found that base humectants evoked 
release of cytokines and pro-inflammatory medi-
ators which is concerning even for vapers who do 
not add nicotine or flavorings to the vape fluid. 
Other researchers agree citing the discovery that 
propylene glycol is converted to propylene oxide 
which can cause a range of health problems rang-
ing from symptoms of infection to carcinogenic 
effects [26, 27]. Vaporizing vegetable glycerine has 
been found to cause irritation of the skin, eyes, 
nares, and esophagus and may also be associated 
with the development of malignacies [33]. Some 
studies are finding that the elevated ratios of vege-
table glycerin and propylene glycol can lead to re-
active oxygen species formation which is linked to 
cardiovascular, neurodegenerative, sensory, and 
psychiatric disorders [34]. Other studies suggest 
that inhaled base ingredients can be converted 
to dangerous substances when heated. Some of 
these ingredients include: acetaldehyde, acrolein, 
acetone, formaldehyde and glyosal. They pose 
a risk of inducing systemic biological alterations 
which can lead to inflammation, central nervous 
system depression, malignancies, and alterations 
in circadian rhythms [35]. These concerning re-
ports and variants in vape use require much more 
investigation to fully understand the implications 
of this new non-tobacco trend. 
Gaps in the literature
Very few studies have been completed look-
ing at the physiological effects of vape use or 
second-hand exposure to vapor despite a call for 
evidence on that end. A few studies discovered 
that vaping (with nicotine) increases heart rate 
(HR) and/or blood pressure (BP) [35, 36]. Var-
davas’ group [37] determined that vaping led to 
respiratory impedance and flow resistance. Addi-
tionally, more data are needed on the short-term 
physiological effects of vaping and second-hand 
inhalation of vapor in order to build up evidence 
to guide public health practices. The relative 
recent increase in popularity of vaping coupled 
with an insufficient amount of research surround-
ing its effects is affecting the ability for health 
practitioners to guide treatment. 
The identified deficiencies in knowledge 
about vaping and the need to contribute knowl-
edge to inform health providers about the safety 
and health effects of vape use prompted the 
physiological variables of HR, BP, respiratory rate 
(RR), blood sugar (BS), oxygen saturation (O2%) 
and pulmonary function tests (PFT) to be chosen 
for examination in this study. Additionally, we 
were interested in understanding the effects of 
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second-hand vapor for people exposed to vapor 
but not actually using the vape as well. Finally, 
we attempted to identify demographic differences 
between the two groups. 
Purpose and hypothesis
The purpose of this study was to examine the 
physiological effects of vaping and second-hand 
exposure to vapor when vaping for twenty min-
utes without nicotine or added flavorings. It was 
expected that both direct inhalation of vegetable 
glycerine and propylene glycol vapor through 
a vape device, and inhalation of second-hand va-
por by those not using a vape device but exposed 
to such vapor would contribute to an increase 
in HR, BP (systolic, diastolic, and mean arterial 
pressure), respiratory rate (RR), and blood sugar 
(BS). We also hypothesized that there would be 
a decrease in percent of blood oxygen saturation 
and pulmonary function test (PFT) results. 
Materials and methods
Design and procedure
The study utilized a mixed-factorial experi-
mental design with one “between groups” factor 
(i.e., participants who directly vaped versus 
participants who did not directly vape but were 
exposed to second-hand vapor), and eight re-
peated measures of ‘within subjects’ factors (i.e., 
measurements of each of the eight physiological 
variables both before and after vaping or exposure 
to second hand vapor). Institutional Review Board 
(IRB) approval was obtained from the institution 
of the first author (i.e., University of Blinded for 
Review) prior to the commencement of the study. 
Participants from both the vape and non-
vape groups were commingled in data gathering 
sessions such that non-vape participants were 
sat next to vape participants. For each session, 
participants first provided informed consent and 
then were asked to complete a demographic and 
health history questionnaire. Thereafter, all phys-
iological variables were measured. Next, vaping 
participants were given a Sorin® vape device filled 
with a 70/30 mix of vegetable glycerin and pro-
pylene glycol and asked to vape for twenty min-
utes. The fluid contained no nicotine or flavorings 
in order to determine the physiological effects of 
the base vape fluid without additives. Non-vapers 
were asked to sit next to the vaping participants 
during the same time frame. At the conclusion 
of the twenty minutes of vaping, physiological 
measurements were taken again. 
Sample
A convenience sample of adult volunteers 
was solicited using social media and direct re-
cruitment by the researchers. A total of 148 vol-
unteers agreed to participate. Approximately half 
of the participants self-identified as vape users 
and were assigned to the vape group, while the 
remaining participants self-identified as non-vape 
users and were assigned to the non-vape (i.e., 
vape-exposure) group. Participants were asked 
to not eat or vape at least sixty minutes prior to 
data collection. 
Measures
Physiological variables measured included: 
HR measured in beats per minute (bpm), respi-
ratory rate (RR) measured in breaths per minute, 
percent of blood oxygen saturation (% O2 sat) mea-
sured using a pulse oximeter, BP measured using 
manual blood pressure cuff with ausculation for 
systolic (SBP) over diastolic (DBP) pressures (mm 
Hg), mean arterial pressure (MAP) determined by 
calculating SBP + 2(DBP)/3, pulmonary function 
tests (PFT) measured using a peak flow meter 
(% of personal best average of three attempts), 
and blood sugar (BS) measured using a glucom-
eter (mg/dL). 
Results
Demographic characteristics and participant 
responses to all health variables for the entire 
sample are reported separately for each experi-
mental group (i.e., non-vape and vape) in Table 
1. Analyses that were completed to determine if 
the two groups differed on any of these variables 
are also reported in the table. Of these analyses, 
only those involving gender and smoking habits 
emerged significant. The finding for smoking 
habits became non-significant when participants 
identified as former smokers were removed from 
the analysis. It was also interesting to note that 
while the two groups did not demonstrate statis-
tically significant differences, a higher frequency 
of vapers reported health risk factors including 
alcoholism, use of alcohol, cigarette use, former 
cigarette use, and mental illness compared to the 
non-vaping participants. Conversely, participants 
in the non-vaping group reported a higher fre-
quency of a positive family history for alcoholism. 
Basic descriptive statistics were calculated 
for age and all outcome variables of interest for 
the entire sample, as well as for the non-vape and 
Molly L McClelland et al., Effects on vital signs after twenty minutes of vaping
507www.journals.viamedica.pl
Table 1. Descriptive statistics and frequencies for all demographic and health variables for the pooled sample and the 







Tests of group 
differences
Age
F (1,136) = 0.76, p = 0.386
   Mean 23.19 22.64 23.76
   Standard deviation 9.23 8.08 10.30
   Minimum–maximum 18–78 18–78 18–62
Gender
c2 (1) = 10.30, p = 0.001
   Male 63 22 41
   Female 79 49 30
   Missing 6 4 2
Race
c2 (1) = 3.36, p = 0.067
   White 112 60 52
   Not white/mixed 29 10 19
   Missing 7 5 2
Family history of alcoholism
c2 (1) = 0.34, p = 0.561
   No 118 58 60
   Yes 29 16 13
   Unsure/missing 1 1 0
Alcoholism
c2 (1) = 2.09, p = 0.149
   No 142 73 69
   Yes 2 0 2
   Unsure/missing 4 2 2
Uses alcohol
c2 (1) = 2.98, p = 0.084
   No 42 26 16
   Yes 102 47 55
   Missing 4 2 2
Smoking habits
c2 (2) = 8.55, p = 0.014
   Non-smoker 133 72 61
   Smoker 6 1 5
   Former smoker 5 0 5
   Missing 4 2 2
Drug addiction
c2 (1) = 0.00, p = 0.989
   No 139 70 69
   Yes 4 2 2
   Unsure/missing 5 3 2
Mental illness
c2 (1) = 0.49, p = 0.485
   No 111 58 53
   Yes 31 14 17
   Unsure/missing 6 3 3
For age, four cases were missing data, so calculations based on N = 144 for the pooled sample, n = 73 for the non-vape group, and n = 71 for the vape group, 
respectively. For tests of group differences, one-way analysis of variance was used with age, and chi-square tests of independence were used for all other variables. 
For smoking habits, the chi-square analysis was run a second time after excluding former smokers. The result emerged non-significant; c2 (1) = 3.23, p =0.072
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vape groups separately. As well, skew and kurtosis 
were computed for all variables. An examination 
of these statistics revealed evidence of a severe 
non-normality of score distributions for multiple 
variables as reflected in the elevated skew (i.e., 
values of 2 or greater) and/or kurtosis (i.e., values 
of 7 or greater). In addition, most variables appear 
to have extreme values (i.e., values that are three 
standard deviations below or above the mean). 
Study outcomes as a function of demographic 
and health variables
Prior to running the main analyses, we 
thought it would be worthwhile to examine the 
extent to which all main study outcome variables 
may be influenced by demographic and health 
variables. As such, we computed product-moment 
correlations with age and outcome variables via 
one-way Analysis of Variance (ANOVA) where-
in the outcome variables served as dependent 
variables, and the remaining demographic (e.g., 
gender, race) and health variables (i.e., smoking 
habit, family history of alcoholism, alcoholism, 
use of alcohol, addiction, and mental illness) 
were used as independent variables. While not 
reported in this article due to length restrictions, 
one or more statistically significant results was 
obtained with all variables except self-reported 
alcoholism. The most frequent significant results 
were found for gender, followed by age, addiction, 
family history of alcoholism, alcohol use, race, 
mental illness, and smoking habit, respectively. 
Main analyses
Given the research design used in this study, 
the most straightforward and efficient approach 
to analysis would have involved the completion 
of eight mixed factorial ANOVAs with the groups 
(i.e., non-vape vs. vape) as the “between groups” 
independent variable, and the pre-post measure-
ments of the outcome variables (i.e., pre-post 
systolic blood pressure, diastolic blood pressure, 
mean arterial pressure, heart rate, blood oxygen 
saturation, respiratory rate, blood sugar, and pul-
monary functions) as the ‘within subjects’ vari-
ables. However, problems with the non-normality 
of score distributions and/or extreme outlying 
values of many variables challenged the appro-
priateness of using such a statistic because it is 
known to be sensitive to violations of assumptions 
regarding normality, and also because extreme 
values have a distorting influence on mean scores. 
In lieu of the mixed factorial ANOVAs, we 
decided to adopt a multi-staged approach to data 
analysis. First, we completed one-way ANOVAs 
using each outcome variable as the dependent 
variable and experimental groups as the inde-
pendent variable. Second, we re-ran ANOVAs 
after excluding extreme values on the dependent 
variable whenever extreme outliers were found. 
This was done to ensure that results were not 
skewed due to the influence of outliers. Third, we 
ran Mann-Whitney tests using all data including 
outliers. This is the non-parametric equivalent 
of the one-way ANOVA and is not influenced by 
non-normality. The results of these three sets of 
analyses using pre-test, post-test, and pre-post 
difference variables can be found in Tables 2 and 
3, respectively. 
An examination of the results for the pre-test 
variables in Table 2 revealed significant findings 
in all analyses for systolic blood pressure, mean 
arterial pressure, and pulmonary functions with 
the vape group obtaining the significantly higher 
mean score in all cases. Effect sizes as reflected 
in eta-squared are all small. In addition, while 
the one-way ANOVA for blood oxygen saturation 
was found to be non-significant in all the cases, 
the result became significant when excluding 
outliers. The Mann-Whitney test result was also 
significant. The effect size, however, is small. The 
non-vape group obtained the higher mean score. 
In terms of the post-test variables in Table 2, 
consistently significant results with small effect 
sizes were obtained for systolic blood pressure, 
diastolic blood pressure, mean arterial pressure, 
and pulmonary function tests. In all cases, the 
vape group produced the higher mean score. Al-
ternatively, an inspection of Table 3 shows that no 
significant results were found with the pre-post 
difference scores. This indicates that the degree 
of change in values from pre- to post-test was not 
markedly different across the non-vape and vape 
groups for any of the measured outcome variables. 
To further test for the robustness of results, 
two additional sets of analyses were completed. In 
the first, outliers on both the dependent variable 
and age were excluded and one-way ANOVAs 
were re-computed. In the second, with the same 
outliers removed, we completed Analyses of 
Covariance (ANCOVA) controlling for age and 
gender. These variables were selected for use as 
covariates based upon the large number of statis-
tically significant findings that we obtained when 
examining their association with the outcome 
variables. 
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Analyses that emerged non-significant in 
the first three sets of analyses continued to be 
non-significant in these additional analyses. The 
significant findings found with pre-test systolic 
blood pressure, pre-test mean arterial pressure, 
pre-test blood oxygen saturation, post-test systolic 
blood pressure, and post-test pulmonary func-
tioning came out non-significant after excluding 
outliers on these variables and age and when 
controlling for age and gender. Pre-test pulmonary 
function, post-test diastolic blood pressure, and 
post-test mean arterial pressure were found to 
remain significant after excluding outliers on the 
variables as well as age but became non-signifi-
cant in the ANCOVAs. Overall, it appears that all 
significant “between-group” results can be seen 
as a product of the influence of outlier scores 
and/or covariates. 
To provide a more fulsome evaluation of the 
effects of vape exposure on the non-vape and 
vape groups, we elected to complete a number 
of repeated measures ANOVAs for each group 
separately. Akin to the between-groups analyses, 
we used a multi-staged approach where we first 
examined the pairs of pre-post outcome variables 
using all available data for each group. Thereafter, 
we ran a second set of ANOVAs excluding outliers 
on both the pre- and/or post-test outcome vari-
ables. Third, we ran Wilcoxon tests for each pre-
post variable pair. This statistic is the nonpara-
metric equivalent to a paired-samples t-test and 
repeated measures ANOVA and is not influenced 
by non-normality or extreme outliers. Results of 
these analyses can be found in Table 4.
Inspection of the findings for the non-vape 
group only showed significant results with small 
to medium effect sizes for systolic blood pressure, 
diastolic blood pressure, and mean arterial pres-
sure. In all instances, pre-test mean scores were 
significantly higher. No other significant results 
were found for the non-vape group. For the vape 
group, systolic blood pressure, mean arterial pres-
sure, and heart rate (all higher at pre-test) came 
out significant with small to medium effect sizes.
Lastly, we ran two additional sets of repeated 
measures ANOVAs. In one set, outlier pre- and/or 
post-test scores on the outcome variable were 
excluded, as were outliers on age. In the sec-
ond, outliers continued to be excluded and both 
gender and age were used as covariates. Results 
were mostly the same as they were in the first 
three sets of analyses. For the non-vape group, 
systolic blood pressure, diastolic blood pressure, 
and mean arterial pressure remained statistically 
significant with small-to-medium effect sizes. For 
the vape group, systolic blood pressure remained 
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Pre-post difference scores were computed by subtracting post-test values from pre-test values for each variable. One-way ANOVAs with Outliers Excluded were only 
computed when there was evidence of one or more extreme outliers (i.e., values greater than 3 standard deviations from the total pooled mean) on the dependent 
variable. Mean arterial pressure was estimated using the formula [systolic blood press + (2 × diastolic blood press)] / 3. Asterisk (*) means that Levene’s test was 
significant so homogeneity of variance cannot be assumed
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Table 4. Results of analyses examining all dependent variables at pre-post test for experimental groups separately
Pre-test Post-test Repeated measures ANOVA
Repeated measures ANOVA 
with outliers excluded Wilcoxon test
Mean [SD] Mean [SD] F [dfn/dfd]  P Partial eta2 F [dfn/dfd] P Partial eta2 Z P























12.86 0.001 0.15 — — — -3.15 0.002






































































5.57 0.021 0.07 — — — -2.43 0.015






0.022 0.07 4.49 
(1, 71)


































0.605 — — — -0.21 0.833
Repeated measures ANOVAs with outliers excluded were only computed when there was evidence of one or more extreme outliers (i.e., values greater than 3 standard 
deviations from the group mean) on the dependent variable at pre- and/or post-test. Mean arterial pressure was estimated using the formula [systolic blood press + 
(2 × diastolic blood press)] / 3
significant in both sets of analyses with medium 
effect sizes. Mean arterial pressure continued 
to be significant when outliers were removed 
but dropped below statistical significance when 
covariates were included. Finally, heart rate 
emerged non-significant in both analyses.
Discussion
The findings of this investigation provide 
an interesting and somewhat unexpected set 
of results. In relation to our hypothesis which 
predicted that HR, BP, respiratory rate (RR), 
and blood sugar (BS) would increase while the 
percent of blood oxygen saturation (O2%) and 
results of pulmonary function testing (PFT) would 
decrease as a function of vaping and/or exposure 
to second-hand vapor, our pre-post analyses 
indicated that, for the vape group, SBP, mean 
arterial pressure (MAP), and HR significantly 
decreased after vaping. However, only the result 
for SBP remained significant when controlling 
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for age and gender and/or excluding outliers. For 
the non-vape group, all three BP variables (SBP, 
DBP, and MAP) were significantly lower after ex-
posure to second-hand vapor. When considering 
our ‘between-groups’ analyses, the vape group 
produced significantly higher pre- and post-va-
ping mean values on SBP, MAP, and PFTs while 
obtaining a significantly higher mean DBP at 
post-vape only. Nevertheless, all of these differ-
ences ceased being statistically significant when 
excluding outliers and/or when controlling for age 
and gender. As well, “between-group” analyses of 
mean pre-post difference scores were consistently 
non-significant indicating that the two groups 
did not substantively differ from each other in 
their physiological response to vaping/exposure 
to vapor. Based upon our findings, it appears that 
vegetable glycerine and propylene glycol e-juice 
without flavoring or nicotine does not seem to 
have any markedly negative immediate physi-
ological effects regardless of whether they were 
directly vaped or inhaled through second-hand 
vapor.
The fact that robust decreases in one or more 
mean BP variables were found for both groups 
after vaping or exposure to vapor is counterin-
tuitive but may be explained as a function of all 
participants becoming more relaxed with the ex-
periment as participation in the study proceeded 
(e.g., participants in both groups became more 
comfortable with the experimental situation and 
interacting with each other). If this is correct, then 
it may be worthwhile for future researchers using 
a similar methodology to ensure that participants 
are at ease with each other and with the study 
conditions prior to vaping or exposing partici-
pants to vapor. It might also be good to obtain two 
or more baseline (i.e., before vaping or exposure 
to vapor) physiological measurements so that the 
effects of any initial discomfort can be mitigated 
through the averaging of multiple measurements. 
Demographic findings suggest that people 
who chose to vape show a trend toward report-
ing higher levels of other health-risk behaviors 
including abusing alcohol and cigarette use. Va-
pers also reported a higher frequency of drinking 
alcohol and have a higher incidence of mental 
illness compared to people who do not vape. 
Conversely, people who do not vape reported 
a higher incidence of a positive family history 
of alcoholism. However, the absence of statisti-
cally significant differences between the groups 
on most of these variables (i.e all but smoking) 
makes it difficult to ascertain if the higher levels 
of health-risk behaviors seen with our sample are 
reflective of robust differences that would be seen 
in the population at large. 
Limitations of the study
The study was limited by the skewed gen-
der and race distribution in the sample. There 
were significantly more females than males and 
a disproportionately high percentage of Cau-
casian participants compared to other ethnic 
groups. A more equitably diverse sample may 
yield different results. Additionally, the age of 
participants was established as needing to be 
greater than 18. However, there was no upper 
limit and since age can affect some vital signs, 
similar future studies could consider capping the 
upper age limit.
Conclusions
One of the main goals of medical profes-
sionals is to promote health and reduce risk. It is 
currently unclear if long-term vape use is a safe 
alternative to smoking or if the use of e-cigarettes 
can help smokers quit smoking [38, 39]. The out-
break of lung diseases portrayed in many media 
outlets during summer 2019 created public aware-
ness and concern regarding the health effects of 
vape use. Policy makers have been implementing 
regulations on vaping in an attempt to keep the 
public safe, but this is often done with insuffi-
cient evidence [40]. Medical providers need to 
stay abreast of current vaping research in order 
to know how to best guide patients, the public 
at large, and contribute to evidenced based laws, 
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